Journey Medical Corporation, a subsidiary of Fortress Biotech, secured a contract with the third major group purchasing organization in the United States. The agreement, effective April 1 2026, expands coverage of the rosacea treatment Emrosi to roughly 85 % of all commercial lives nationwide, increasing the number of covered commercial lives from about 100 million to more than 150 million.
The new coverage removes a significant payer barrier that had limited Emrosi’s reach. By securing contracts with all three major GPOs, Journey Medical positions the drug as a preferred option for a broad swath of employers and health plans, which is expected to accelerate prescription uptake across the U.S. market.
The expanded payer access is projected to reduce reliance on co‑pay assistance programs, improve net sales margins, and support the company’s goal of achieving peak U.S. sales of $200 million for Emrosi. The broader coverage is also expected to drive higher prescription volumes, which in turn should translate into stronger revenue growth for the company.
This milestone aligns with Fortress Biotech’s strategy of leveraging its incubation model to generate scalable, non‑dilutive revenue streams through partner success. By securing GPO contracts, Journey Medical can monetize its commercial platform without diluting equity, reinforcing Fortress’s focus on high‑margin, partnership‑driven growth.
Claude Maraoui, Co‑Founder, President, and CEO of Journey Medical, said, “We are extremely pleased with the completion of this milestone for Emrosi™.” He added, “Our focus on delivering cost‑effective access to high‑quality dermatology therapies is expected to expand coverage and improve patient access, positioning Emrosi™ for sustained commercial growth.” Maraoui also noted, “Now that our contracts have been secured with the three major GPOs, we look forward to continuing to increase coverage for Emrosi™ for patients nationwide by converting access into coverage.”
The contract represents a key commercial milestone for Journey Medical and Fortress Biotech, removing a major payer hurdle and setting the stage for accelerated growth of Emrosi in the U.S. market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.